UC Davis to ship GemPharmatech mouse models in U.S.
GemPharmatech and the University of California, Davis (UC Davis) have entered into a service agreement for the UC Davis Mouse Biology Program to provide services to reanimate, cryopreserve, and ship live mice to GemPharmatech customers in the U.S. Read More
Porton Biologics establishes CGT CDMO services with $61.4M in financing
Porton Biologics, a subsidiary of cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) Porton Pharma Solutions, has closed 400 million RMB ($61.4 U.S.) in financing. The funds will be used for the construction and operation of the company's commercial production facility. Read More
Precision BioSciences reacquires rights to allogeneic CAR T programs
Precision BioSciences has entered into an agreement to reacquire global rights to all chimeric antigen receptor (CAR) T partnered programs covered under its development and commercial license agreement with Servier. Read More
Relay Therapeutics acquires ZebiAI for $85M
Relay Therapeutics has acquired ZebiAI, a developer of experimental DNA-encoded library datasets using machine learning for drug discovery. Relay hopes the acquisition will accelerate the advancement of its Dynamo platform. Read More
Aceto has acquired A&C to expand biomanufacturing offerings
Aceto has acquired A&C, a global good manufacturing practice manufacturer of specialty excipients, buffers, and process solutions. Read More
Biosplice secures $120M to advance splicing platform
Biosplice Therapeutics has closed $120 million in equity financing to support clinical development of lorecivivint, its small-molecule candidate in phase III clinical development for the treatment of osteoarthritis. Read More
EMA to review GSK, Vir COVID-19 mAb
GlaxoSmithKline (GSK) and Vir Biotechnology announced that the European Medicines Agency (EMA) has started a review of VIR-7831 (GSK4182136), an investigational dual-action SARS-CoV-2 monoclonal antibody (mAb) for the treatment of adults and adolescents 12 years old and over with COVID-19 who do not require oxygen supplementation and who are at high risk of progressing to severe COVID-19. Read More
Brooklyn ImmunoTherapeutics to acquire mRNA tech
Brooklyn ImmunoTherapeutics has paid $1 million to acquire a license for Factor Bioscience's and Novellus' messenger RNA (mRNA) gene editing and cell therapies technology. Read More
Novavax COVID-19 vaccine to be included in combo vaccine study
Novavax announced it will participate in a newly expanded phase II trial to study NVX-CoV2373, its recombinant protein COVID-19 vaccine candidate. The candidate vaccine is one of four that will be studied to evaluate the potential for combined regimens that mix vaccines from different manufacturers to achieve immune protection against COVID-19. Read More
Merck, Ridgeback to advance outpatient COVID-19 therapy to phase III trial
Merck and Ridgeback Biotherapeutics have announced they will move forward with a phase III trial of EIDD-2801/MK-4482 (molnupiravir), an oral antiviral developed for outpatient treatment of people suffering from COVID-19. Read More
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter